Posted by Michael Wonder on 31 May 2022
Priothera receives fast track designation for mocravimod in combination with allogeneic haematopoietic stem cell transplant for post remission therapy of acute myeloid leukaemia patients
31 May 2022 - Priothera today announces that the U.S. FDA has granted fast track designation for mocravimod in combination with allogeneic haematopoietic stem cell transplant for post remission therapy of acute myeloid leukaemia patients.
Priothera is working to initiate the MO-TRANS global Phase 2b/3 study in Europe, US and Japan, to assess the efficacy and safety of mocravimod as an adjunctive and maintenance therapy in adult acute myeloid leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation.
